A

Adicet Bio
D

ACET

0.70710
USD
-0.04
(-5.88%)
مفتوح الان
حجم التداول
2,744
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
58,483,976
أصول ذات صلة
B
BCRX
-0.085
(-0.82%)
10.275 USD
C
CPRX
0.130
(0.55%)
23.650 USD
C
CRIS
0.07000
(2.86%)
2.52000 USD
NVS
NVS
-0.935
(-0.78%)
118.520 USD
P
PRGO
0.090
(0.34%)
26.730 USD
REGN
REGN
-2.17
(-0.41%)
527.22 USD
S
SCYX
-0.00730
(-0.89%)
0.81270 USD
المزيد
الأخبار المقالات

العنوان: Adicet Bio

القطاع: Healthcare
الصناعة: Biotechnology
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.